126 related articles for article (PubMed ID: 38839200)
1. Excess Apolipoprotein B and Cardiovascular Risk in Women and Men.
Johannesen CDL; Langsted A; Nordestgaard BG; Mortensen MB
J Am Coll Cardiol; 2024 Jun; 83(23):2262-2273. PubMed ID: 38839200
[TBL] [Abstract][Full Text] [Related]
2. Remnant cholesterol, LDL cholesterol, and apoB absolute mass changes explain results of the PROMINENT trial.
Doi T; Langsted A; Nordestgaard BG
Atherosclerosis; 2024 Jun; 393():117556. PubMed ID: 38678642
[TBL] [Abstract][Full Text] [Related]
3. Apolipoprotein B and Non-HDL Cholesterol Better Reflect Residual Risk Than LDL Cholesterol in Statin-Treated Patients.
Johannesen CDL; Mortensen MB; Langsted A; Nordestgaard BG
J Am Coll Cardiol; 2021 Mar; 77(11):1439-1450. PubMed ID: 33736827
[TBL] [Abstract][Full Text] [Related]
4. Lipids, Apolipoproteins, and Risk of Atherosclerotic Cardiovascular Disease in Persons With CKD.
Bajaj A; Xie D; Cedillo-Couvert E; Charleston J; Chen J; Deo R; Feldman HI; Go AS; He J; Horwitz E; Kallem R; Rahman M; Weir MR; Anderson AH; Rader DJ;
Am J Kidney Dis; 2019 Jun; 73(6):827-836. PubMed ID: 30686529
[TBL] [Abstract][Full Text] [Related]
5. Association of Apolipoprotein B-Containing Lipoproteins and Risk of Myocardial Infarction in Individuals With and Without Atherosclerosis: Distinguishing Between Particle Concentration, Type, and Content.
Marston NA; Giugliano RP; Melloni GEM; Park JG; Morrill V; Blazing MA; Ference B; Stein E; Stroes ES; Braunwald E; Ellinor PT; Lubitz SA; Ruff CT; Sabatine MS
JAMA Cardiol; 2022 Mar; 7(3):250-256. PubMed ID: 34773460
[TBL] [Abstract][Full Text] [Related]
6. VLDL Cholesterol Accounts for One-Half of the Risk of Myocardial Infarction Associated With apoB-Containing Lipoproteins.
Balling M; Afzal S; Varbo A; Langsted A; Davey Smith G; Nordestgaard BG
J Am Coll Cardiol; 2020 Dec; 76(23):2725-2735. PubMed ID: 33272366
[TBL] [Abstract][Full Text] [Related]
7. Remnant cholesterol predicts cardiovascular disease beyond LDL and ApoB: a primary prevention study.
Quispe R; Martin SS; Michos ED; Lamba I; Blumenthal RS; Saeed A; Lima J; Puri R; Nomura S; Tsai M; Wilkins J; Ballantyne CM; Nicholls S; Jones SR; Elshazly MB
Eur Heart J; 2021 Nov; 42(42):4324-4332. PubMed ID: 34293083
[TBL] [Abstract][Full Text] [Related]
8. Remnant Cholesterol, Not LDL Cholesterol, Explains Peripheral Artery Disease Risk Conferred by apoB: A Cohort Study.
Wadström BN; Pedersen KM; Wulff AB; Nordestgaard BG
Arterioscler Thromb Vasc Biol; 2024 May; 44(5):1144-1155. PubMed ID: 38511326
[TBL] [Abstract][Full Text] [Related]
9. Association of Triglyceride-Lowering LPL Variants and LDL-C-Lowering LDLR Variants With Risk of Coronary Heart Disease.
Ference BA; Kastelein JJP; Ray KK; Ginsberg HN; Chapman MJ; Packard CJ; Laufs U; Oliver-Williams C; Wood AM; Butterworth AS; Di Angelantonio E; Danesh J; Nicholls SJ; Bhatt DL; Sabatine MS; Catapano AL
JAMA; 2019 Jan; 321(4):364-373. PubMed ID: 30694319
[TBL] [Abstract][Full Text] [Related]
10. Associations of LDL Cholesterol, Non-HDL Cholesterol, and Apolipoprotein B With Cardiovascular Disease Occurrence in Adults: Korean Genome and Epidemiology Study.
Yun SY; Rim JH; Kang H; Lee SG; Lim JB
Ann Lab Med; 2023 May; 43(3):237-243. PubMed ID: 36544335
[TBL] [Abstract][Full Text] [Related]
11. Association of Genetic Variants Related to CETP Inhibitors and Statins With Lipoprotein Levels and Cardiovascular Risk.
Ference BA; Kastelein JJP; Ginsberg HN; Chapman MJ; Nicholls SJ; Ray KK; Packard CJ; Laufs U; Brook RD; Oliver-Williams C; Butterworth AS; Danesh J; Smith GD; Catapano AL; Sabatine MS
JAMA; 2017 Sep; 318(10):947-956. PubMed ID: 28846118
[TBL] [Abstract][Full Text] [Related]
12. Low-Density Lipoprotein Cholesterol, Non-High-Density Lipoprotein Cholesterol, Triglycerides, and Apolipoprotein B and Cardiovascular Risk in Patients With Manifest Arterial Disease.
van den Berg MJ; van der Graaf Y; de Borst GJ; Kappelle LJ; Nathoe HM; Visseren FLJ;
Am J Cardiol; 2016 Sep; 118(6):804-810. PubMed ID: 27471056
[TBL] [Abstract][Full Text] [Related]
13. Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men.
Pischon T; Girman CJ; Sacks FM; Rifai N; Stampfer MJ; Rimm EB
Circulation; 2005 Nov; 112(22):3375-83. PubMed ID: 16316964
[TBL] [Abstract][Full Text] [Related]
14. Evaluating the atherogenic burden of individuals with a Friedewald-estimated low-density lipoprotein cholesterol <70 mg/dL compared with a novel low-density lipoprotein estimation method.
Whelton SP; Meeusen JW; Donato LJ; Jaffe AS; Saenger A; Sokoll LJ; Blumenthal RS; Jones SR; Martin SS
J Clin Lipidol; 2017; 11(4):1065-1072. PubMed ID: 28826567
[TBL] [Abstract][Full Text] [Related]
15. Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab.
Hagström E; Steg PG; Szarek M; Bhatt DL; Bittner VA; Danchin N; Diaz R; Goodman SG; Harrington RA; Jukema JW; Liberopoulos E; Marx N; McGinniss J; Manvelian G; Pordy R; Scemama M; White HD; Zeiher AM; Schwartz GG;
Circulation; 2022 Aug; 146(9):657-672. PubMed ID: 35770629
[TBL] [Abstract][Full Text] [Related]
16. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis.
Boekholdt SM; Arsenault BJ; Mora S; Pedersen TR; LaRosa JC; Nestel PJ; Simes RJ; Durrington P; Hitman GA; Welch KM; DeMicco DA; Zwinderman AH; Clearfield MB; Downs JR; Tonkin AM; Colhoun HM; Gotto AM; Ridker PM; Kastelein JJ
JAMA; 2012 Mar; 307(12):1302-9. PubMed ID: 22453571
[TBL] [Abstract][Full Text] [Related]
17. Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk.
Rosenblit PD
Curr Diab Rep; 2019 Nov; 19(12):146. PubMed ID: 31754844
[TBL] [Abstract][Full Text] [Related]
18. Discordance among apoB, non-high-density lipoprotein cholesterol, and triglycerides: implications for cardiovascular prevention.
Sniderman AD; Dufresne L; Pencina KM; Bilgic S; Thanassoulis G; Pencina MJ
Eur Heart J; 2024 May; ():. PubMed ID: 38700053
[TBL] [Abstract][Full Text] [Related]
19. Residual dyslipidemia according to low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B among statin-treated US adults: National Health and Nutrition Examination Survey 2009-2010.
Wong ND; Chuang J; Zhao Y; Rosenblit PD
J Clin Lipidol; 2015; 9(4):525-32. PubMed ID: 26228670
[TBL] [Abstract][Full Text] [Related]
20. Age and Cardiovascular Risk Attributable to Apolipoprotein B, Low-Density Lipoprotein Cholesterol or Non-High-Density Lipoprotein Cholesterol.
Sniderman AD; Islam S; McQueen M; Pencina M; Furberg CD; Thanassoulis G; Yusuf S
J Am Heart Assoc; 2016 Oct; 5(10):. PubMed ID: 27737874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
